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Abstract
Harm-benefit analysis (HBA) underpins the ethical framework of the regulation of animal experiments. This process involves a qual-
itative, and generally subjective, assessment of the potential benefits weighed against likely harms to be caused to animals. However,
there is scope to prospectively quantify this process. A systematic and empirical assessment of historical data can give insights into
why benefits are not realised and the magnitude of harm that animals experience. There is substantial scholarly evidence that risks
to the 3Vs, the three core aspects of experimental validity in animal experiments (internal, external and construct validity) and low
statistical power are limiting the reliability and reproducibility of research. Assessment of the 3Rs (reduction, refinement and replace-
ment) is embedded in HBA and specifically seeks to minimise harm to the animals. However, no formal structure is in place to assess
the likelihood of benefit, and we champion the 3Vs as a scale with which this may be achieved. Ethical approval procedures that
consider the 3Vs and 3Rs using meta-research may be an approach to facilitate HBA. In ethical considerations related to animal
research, there are value judgements that are integral to HBA, which cannot be measured directly. However, a quantitative and
systematic approach is likely to be of added value. The perspective and examples described in this paper relate to laboratory animal
research, but the approaches may lend themselves to different settings involving animals to ensure that decision-making and changes
introduced, for example, to improve animal welfare, are evidence-based.
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Introduction 
Research involving animals is performed for many reasons,
including to understand biology, behaviour, conservation,
diseases, inform the development of novel therapies, test the
safety of agents for regulation and to understand how we
may improve husbandry for animals kept in zoos, farms and
laboratories. Societal interactions with animals extend
beyond animal research, such as consuming them as food,
keeping them as pets, in zoos or on farms, and extermi-
nating those we consider pests. This paper will discuss the
ethical framework we use to determine the appropriateness
of animal use in research and how this may have broader
implications for some societal interactions with animals.
Why do we undertake harm-benefit analysis
(HBA)?
In many jurisdictions, harm-benefit analysis (HBA) is a
legal instrument that underpins the ethical framework for
the regulation of animal experimentation. This social and
ethical evaluation applied to proposed research seeks to
evaluate whether the harms that will be caused to
protected animals, in terms of suffering, pain, distress, and
lasting harm, can be justified by the expected benefit to
humans, animals or the environment. The notion of
benefits differs between different areas; in a zoo, benefits
might relate to conservation of a species; in farming, there
are benefits in increasing animal welfare and business
viability, whilst reducing environmental damage. In the
context of biomedical research, the expected benefits are
to human beings. There is the expectation that the research
will, for example, improve understanding of disease
pathology, identify therapeutic targets and/or lead to the
development or refinement of therapeutics. 
In a 1986 article in the New Scientist, Patrick Bateson
discussed the impending UK legislation to regulate the use
of animals in research — the Animal (Scientific Procedures)
Act 1986 — and the conflicts with those vehemently against
the use of animals in research on moral grounds. He
presented a decision cube (now known as Bateson’s cube)
as a framework to inform ethical considerations in decision-
making processes of animal research (Bateson 1986). There
are three ‘sides’ to the cube:
• The degree of animal suffering;
• The quality of the research;
• The benefits of the findings. 
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Ethical animal research should have clear benefits, be of
high quality and ensure minimal suffering to the animal.
Bateson’s cube was not intended to provide a formal
framework to assess trade-offs between the severity of
harms and potential benefits because the axes of the cube
are not in a common currency, therefore, we cannot balance
these incommensurable properties (Bateson 2005).
However, it was intended to inform sensible decision-
making, such as in HBA. 
The expectation is that HBA considers available current
evidence of the harms to animals and potential benefit in a
manner that is transparent, efficient and accountable; these
evaluations should be performed by a sample of people that
reflect societal concerns of the population. Whilst the eval-
uation of social and ethical issues is inherently subjective, it
is evident that there is a robust and empirical scientific
component that should underpin this undertaking. The 2017
Animal in Science’s Committee review on HBAs in the UK
addresses the current limitations in this process and the
difficulties to ascertain the extent to which all current
available evidence informs this process and how relevant
new data are incorporated as, and when, they become
available (Davies 2018). It may be that some committees
undertaking HBAs do have a process that includes compre-
hensive and empirical up-to-date evidence of harms and
likely benefit, but we are not of aware of any. 
Our proposal seeks to apply an empirical assessment of
experimental validity to assess the quality of research to
weigh against the 3Rs (reduction, refinement and replace-
ment) assessment which will inform an HBA. Whilst assess-
ment of the 3Rs is already embedded in HBA and specifically
seeks to minimise harm to the animals, no formal structure is
in place to assess the quality of the research and thus the like-
lihood of benefit. This builds on Wuerbel’s original descrip-
tion that the three core aspects of experimental validity in
animal experiments (internal validity, external validity and
construct validity; 3Vs) form the basis of such a scale as a
counterpart to the 3Rs (Wuerbel 2017). 
How may we take an empirical approach to
provide added value to HBA?
Meta-research (research on research) provides a transparent
and comprehensive approach to study how research is
performed and interpreted. Its roots are in systematic review,
but a broad range of methodologies may be employed. This
approach applied to assess methods, reporting, evaluation,
reproducibility and incentives, allows us to reach a rigorous
understanding of what makes research reliable, and how it
can be most effectively improved (Ioannidis et al 2015).
Including such systematic and empirical approaches to HBA
that are informed by the totality of relevant research,
evidence may improve how we estimate the likelihood of
benefit and severity of harm. The examples we present are
primarily derived from biomedical research, but these
concepts are just as relevant to veterinary research and may
inform how we assess the welfare of animals in a non-
research setting. Our aim here is to instigate discussion about
how an empirical approach can aid HBA. 
Benefit
For research to be of maximal value, and efficiently realise
its intended benefit, it needs to be robust and of high quality.
Currently, the likelihood of realising intended benefit is
generally determined by assessment of the rigour of scien-
tific questions being addressed by the intended research and
the calibre of the scientist responsible for the research. In an
academic setting, much of this evaluation is formally
assessed prior to an HBA. The importance of a research
question is assessed during the competitive grant awarding
process. Because most research seeking ethical approval has
already been deemed worthy for funding, this may influence
ethical approval. This process is inextricably linked to the
reputation of the lead scientist who is judged against criteria
related to the quality of the journals in which they publish
their research and their ability to secure competitive research
funds. Unfortunately, there is no evidence that this assess-
ment of academic success correlates with high experimental
validity and reproducibility. We would argue that assessment
of experimental validity offers a more appropriate correlate
of the degree of purported benefit that is likely to be
achieved. Laboratory animal research, particularly health-
related research, has been blighted by positive findings
observed in animal models that have not translated to similar
effects in human studies (van der Worp et al 2010) and irre-
producibility of findings between laboratories (Nosek &
Errington 2017). Substantial meta-research has identified
many limitations in the way in which we perform experi-
ments using animal models of disease that likely contributes
to this translational failure (Macleod et al 2015). We propose
that an assessment of experimental validity should be an
integral component of HBA. 
Experimental validity refers to the extent to which variables
influence the observed effects and the generalisability of
these findings to other settings. There are various compo-
nents to this validity that, if compromised, threaten the
robustness of an experiment. Operationally, we define:
‘internal validity’ as the strength of the cause-effect relation-
ship, eg whether the observed effects are due to the interven-
tion rather than other unknown systematic biases; ‘external
validity’ as the extent to which experimental inferences can
be generalised, eg to other laboratories and/or, in the context
of modelling human disease, to humans; ‘construct validity’
as the extent to which an outcome measure or experimental
model measures what it purports to. 
Systematic scrutiny of in vivo health research has allowed
us to quantify how rarely, in some areas, the expected
benefit is realised. In in vivo stroke research, of more than
1,000 interventions tested in animal studies, 596 were found
to substantially improve outcome. Of these, 97 were tested
in humans of which only one therapy was shown to be
effective (O’Collins et al 2006). This level of attrition is
high and the prior probability of developing an effective
stroke therapy for humans is extremely low. Much meta-
research has focused on the internal validity of experiments,
and the presence and impact of potential threats to this
validity. These include, but are not limited to, selection bias,
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performance bias, and detection bias which may be
addressed by undertaking measures to reduce risks of bias,
such as randomisation and blinding (Macleod et al 2015).
Dissemination of these findings has been associated with
improvements in the conduct and reporting of measures to
reduce risks of bias in stroke experiments (McCann et al
2016; Minnerup et al 2016). 
Assessment of internal validity should include whether
appropriate controls have been used and measures to reduce
the risk of bias have been undertaken. The internal validity
of an experiment may be threatened by a range of biases.
Selection bias occurs when there are systematic differences
between study groups at the start of an experiment.
Performance bias occurs when systematic differences occur
in how the groups are handled during a study, and detection
bias occurs when systematic differences occur between
groups in how outcomes are ascertained, diagnosed, or
verified. Measures to mitigate the risk of these biases
include randomisation, allocation concealment and blinded
(masked) assessment of outcome. Vogt and colleagues have
demonstrated that, in Switzerland at least, few study
protocols submitted for ethical evaluation report measures
to reduce the risk of bias (2–19%) and corresponding publi-
cations report similarly low values (0–34%) (Vogt et al
2016). Similar analyses assessing the reporting of measures
to reduce risks of bias in the published literature show
equally high threats to internal validity (Macleod et al
2015). Across pre-clinical research domains, meta-research
has demonstrated that studies that do report these measures
to reduce risks of bias are associated with overestimated
treatment effects (Crossley et al 2008; Macleod et al 2008;
Vesterinen et al 2010; Rooke et al 2011; Hirst et al 2013). 
External validity, our ability to replicate findings beyond the
single laboratory to demonstrate the robustness of an effect,
is essential (Wuerbel 2000). Limits to the external validity
of pre-clinical research have been described as key contrib-
utors to the replication crisis and translational failure. To
date, meta-research to improve the external validity of pre-
clinical research has focused on the reporting of in vivo
studies (eg characterisation of the presence and impact of
reporting biases). Our predisposition in favour of ‘positive’
findings, particularly in academia, has led to an environ-
ment in which the direction and magnitude of findings are
more likely rewarded than research studies performed to a
high degree of experimental validity. Thus, neutral or
conclusive findings in contrast to the alternative hypothesis
carry little acclaim or reward. The major fallout of this pref-
erence has led to substantial publication bias in the life
sciences. These biases lead to the totality of evidence over-
estimating treatment effects by about one-third (Sena et al
2010) and an over-representation of statistically significant
results than would be expected (Tsilidis et al 2013). It is
reasonable to expect that if animals are used in experiments
then these data should be disseminated, irrespective of their
findings, to contribute to our distillation of knowledge;
experimental data that are never disseminated will not be
able to do this. Commitment to disseminate research
findings that use protected animals should be considered in
HBA, akin to the requirement to disclose findings from
interventional clinical trials (Moorthy et al 2015). The
mechanism to implement such a requirement is not straight-
forward. At least in the UK, licence applications ask for a
data dissemination strategy, but compliance is not formally
assessed. Assessing compliance may facilitate the mitiga-
tion of publication bias. However, it is likely that different
types of research require different strategies. For example,
Kimmelman and colleagues (2014) propose distinguishing
between exploratory and confirmatory research, which
would provide scientists with the freedom to explore and
innovate (exploratory research) in contrast to robust and
reproducible outputs (confirmatory research). For confirma-
tory research, a more robust approach should require studies
to be pre-registered in an animal study registry akin to those
required for clinical trials. The complexities of such an
endeavour for animal research have been investigated
(Wieschowski et al 2016) and animal-specific platforms
have recently been launched (preclinicaltrials.eu) or are in
the pipeline (The German Federal Institute for Risk
Assessment [BfR], personal communications 2018)
providing an avenue for researchers to do this. However,
this should not exempt researchers conducting exploratory
research from a commitment to disseminate their findings,
even if pre-registration is not appropriate.
Threats to external validity due to the way in which experi-
ments are performed (ie experimental design) are also
pertinent to the likelihood of realising benefit. For example,
the role of experimental standardisation has generally been
overlooked as a threat to external validity. Contrary to
conventional wisdom that standardisation guarantees repro-
ducibility (Beynen et al 2003) both theoretical (Wuerbel
2000; Voelkl & Wurbel 2016) and empirical (Crabbe et al
1999; Richter et al 2009, 2010; Kafkafi et al 2017) evidence
indicates that rigorous standardisation may contribute to
poor reproducibility. This is because the interaction between
animal genotype and environmental conditions results in a
specific phenotypic state that determines experimental
response. The resulting range of response variation (the
reaction norm) is seen as a nuisance that researchers often
seek to eliminate through standardisation. Researchers can
seek to formally sample from across the reaction norm by
undertaking efforts to split experiments into multiple inde-
pendent replicates (batches) (Paylor 2009), introducing
systematic variation (systematic heterogeneity) (Richter et al
2010, 2011) of relevant variables (eg strains, housing condi-
tions, tests, etc) or by implementing multi-centre study
designs (Wodarski et al 2016; Voelkl et al 2018). Multi-
centre studies allow us to sample across the reaction norm by
utilising differences in environmental factors between labo-
ratories, increasing generalisability and the likelihood of
reproducibility. In some legal jurisdictions (eg Germany),
animal experiments that address a research question that is
deemed to have been answered already would not be granted
ethical approval. It is unclear how the validity of such exper-
iments is taken into account and how reproducible these
findings may be when a research question is deemed to have
been answered. A more prudent approach would be to assess
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the experimental validity, including the generalisability, of
studies addressing the same central hypothesis. At present,
the lack of a structure to determine, or even consider,
whether a central hypothesis has been robustly confirmed
may cause problems for those wishing to undertake replica-
tion studies (or even multi-centre studies) to validate
findings in an independent laboratory; an approach counter-
intuitive to good science (Mogil & Macleod 2017). 
In the context of pre-clinical studies of human diseases
associated with co-morbidities (eg age, diabetes or hyper-
tension in stroke) there is evidence that the majority of
studies use young healthy male rats to model the disease
and that when co-morbidities are introduced these experi-
ments manifest smaller treatment effects (Sena et al 2007).
Whilst it is not appropriate, nor desirable, that every in vivo
study uses animals with co-morbidities or is multi-centre in
its design, it is important to describe the next level of
research that a study intends to inform and thus the intended
external validity of the study. For example, in proof-of-
principle studies where the intention is to inform the more
complex experiments that model co-morbidities, the appro-
priate design, will differ from experiments that are intended
to inform clinical trial design. 
Modelling human diseases can be complex. Appropriate
animal models and outcome measures are required to
demonstrate comparable aetiology, and similar pathophysi-
ology (face validity) and response to treatment (predictive
validity) as observed in the human disease (Willner &
Mitchell 2002). We describe construct validity as the exper-
imental demonstration of these similarities. Assessment of
construct validity should take into account the animal
model, the test or outcome measure and the attribute it is
intended to measure (Wuerbel 2017). Assessment of the
tests and outcome measures should consider whether these
are indeed measuring similar or independent constructs.
Further, no one model can encapsulate the entirety of the
heterogeneity observed in many diseases but understanding
the construct validity of these models is important and
providing evidence of face and predictive validity of these
models, in the context of human diseases, is essential to
underscore their appropriateness. For many diseases, a wide
range of models have been established across many species.
It has been reported that model selection is often based on
the perceived aspect of the disease they are representing or
of the mechanism of action of the intervention in question
(Macrae 2011). However, as evidenced from this example
of ischaemic stroke that describes many different models
and variations of those models, it is unclear whether the
panoply of available models and outcomes, and the conse-
quent limits to their construct validity, are considered in this
selection and the extent to which laboratory convention
plays in this decision-making. Clear justification of model
and outcome choice to ascertain construct validity could
substantially improve our assessment of likely benefit.
Whilst limiting threats to experimental validity does not
guarantee that benefit will be realised, it does provide a
quantitative component related to the likelihood of success.
This, alongside the other qualitative and somewhat
subjective judgements we make of the likelihood of
benefit and need, may improve how we approach the
benefits arm of an HBA. Careful scrutiny of experimental
validity using the 3V principles moves us from taking
validity and reproducibility for granted (Wuerbel 2017)
when assessing the likelihood of benefit.
Harm
Presently, in HBA, the likelihood of benefit is balanced
against the estimated harm caused to animals. Our approach
to assessing the harm to animals of proposed research is
embedded in our application of the 3R (reduction, replace-
ment and refinement) principles (Russell & Burch 1959).
Many jurisdictions specifically require formal assessment
of these principles and that those undertaking HBAs are
satisfied that the research questions cannot be answered by
using fewer animals (reduction), by using non-sentient
animals or alternatives to in vivo models (replacement), and
that animal welfare is maximised and less harmful proce-
dures are not available (refinement). The implication being
that this approach will ensure the suffering, pain, distress,
and lasting harm to the animals is minimised as much as
possible. Public opinion polls indicate that the majority of
the public accept the use of animals in scientific research as
long as there is no unnecessary suffering to the animals and
there is no alternative (Leaman 2014).
The concept of reduction seeks “to reduce the numbers of
animals used to obtain information of a given amount and
precision.” It is reasonable to argue that using too few
animals to reliably answer a research question is unethical
because these animals do not accurately contribute to our
scientific knowledge. In fact, the National Centre for the
Refinement, Replacement and Reduction of Animals in
Research (NC3Rs) set up by the UK Government to oversee
and promote laboratory animal welfare research, introduced
a contemporary definition of reduction to reflect this
“Appropriately designed and analysed animal experiments
that are robust and reproducible, and truly add to the
knowledge base.” The appropriate number of animals
required to answer a research question is an empirical
question that can be determined by undertaking a sample
size calculation based on estimates of variance, the desired
magnitude of effect and the desired statistical power to
detect this effect; yet, this estimation is rarely reported
(Sena et al 2007; Macleod et al 2015). Post hoc calculations
based on published data suggest that experiments should be
substantially larger than reported in the literature. Indeed,
the typical ischaemic stroke study is powered at only
30% — even if the effect being sought is present, there is a
70% chance that it will not be detected (CAMARADES,
data on file). The reliability and accuracy with which
conclusions are drawn from statistical tests are dependent
on adequate sample size and the use of an appropriate statis-
tical test for the type of data. Ioannidis has shown (Ioannidis
2005) that underpowered studies, resulting from inadequate
sample sizes, are likely to have low positive predictive
value, which is particularly relevant in laboratory research
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where statistical power is rarely considered (Sena et al
2007). Most animal studies are carried out under tightly
defined conditions in healthy young animals (ie designed
explicitly to show large effect sizes) and are underpowered
to detect potentially important but smaller treatment effects.
Studies seeking to detect smaller effects in more generalis-
able, less tightly controlled conditions in older animals with
relevant co-morbidities are even more at risk of being
underpowered (Festing & Altman 2002, 2005). Sample size
calculations are most suitable for confirmatory research or
exploratory research using inferential statistics.
When undertaking HBA, in addition to considering the
design of the study, a meta-approach could be used to
determine the importance of the research question. This
may contribute to reducing the number of experiments
conducted using animals.
The concept of refinement seeks to utilise methods that
minimise pain, suffering, distress and lasting harm to animals
and improve welfare. Given the panoply of approaches to
animal experimentation and the ability to apply refinement
approaches to all aspects of animal uses (eg from housing,
husbandry, to the tests used) there are options to estimate the
relative impact of pain and distress at these different stages of
experimentation. Using a systematic approach, we can provide
empirical evidence of the relative impact of experimental
design choices on measures of animal welfare. For example,
environmental enrichment has been widely advocated, in labo-
ratory and zoo settings, to improve the welfare and the quality
of research (Baumans 2005). An added potential benefit of
environmental enrichment is the increased environmental
heterogeneity within a study, thus increasing the sampling of
the reaction norm, for improved external validity. However, in
a systematic review describing the modelling of
chemotherapy-induced peripheral neuropathy, only five of 341
publications (1%) reported home-cage enrichment (Currie
et al 2018). An additional consideration of animal welfare in
the modelling of pain is post-operative analgesia. There is no
consensus on the effect of post-operative analgesia regimens
on experimental outcomes and in experiments using animal
models of neuropathic pain often only minimal analgesics are
given. There is an ongoing meta-research project to compare
the effect of different post-operative analgesia regimens on
modelling (Currie et al 2018; http://www.dcn.ed.ac.uk/
camarades/research.html#protocols) to provide empirical
evidence to support these decisions. This project may support
the hypothesis that robust analgesics can be administered to
animals and only ceased for a window when measurements
are taken. This could potentially reduce the duration of
suffering that animals experience during pain-modelling
experiments. In the modelling of spinal cord injury, by
comparing findings from studies where different outcomes
have been measured in the same cohort of animals, there is
evidence that subjecting animals to additional distress, by
subjecting them to multiple tests, provided no added value in
terms of demonstrating effectiveness (Antonic et al 2013).
Providing empirical evidence to determine whether less-
noxious tests are as predictive as more severe alternatives and
whether multiple tests are necessary would be a useful
addition to the implementation of refinement strategies. 
Replacement seeks to determine whether it is possible to
avoid or replace the use of animals in research. This may
refer to the use of non-in vivo methods, such as in vitro or
computational models. Further, relative replacement sets
out to answer the same research question using non-sentient
animals or in early-life stages before legal protection exists.
When researchers justify the use of animals in research, it is
not immediately apparent how this is formally assessed
beyond statements from researchers that alternatives are not
appropriate to address their research question. Central
resources to identify alternatives are limited, we are only
aware of a German-speaking one (The German Centre for
Documentation and Evaluation of Alternatives to Animal
Experiments [ZEBET]), and few researchers formally
search for alternatives in the design of their experiments
(van Luijk et al 2011). The NC3Rs 2017–2019 strategy
discusses the 3Rs ‘valley of death’, the gap between the
development of new 3Rs technologies and approaches and
their adoption into routine use. They have recently launched
a platform in collaboration with F1000 to address this
problem (Percie du Sert & Robinson 2018). However, this
platform is only for NC3Rs-funded research meaning that
3Rs-relevant research not funded by the NC3Rs will not
contribute to conquering this valley of death. Further,
relevant research that does not explicitly highlight the 3Rs
opportunities compounds this problem. A formal require-
ment in license applications to detail efforts made to
identify 3Rs opportunities could make the development of a
more comprehensive tool more likely and highly impactful.
In addition, a strategy to better reward the legacy of 3Rs
developments may facilitate more effective implementation
of 3Rs approaches. 
Practical applications
Providing an empirical component to HBA that considers
both the 3Rs and 3Vs underscores the link between good
animal welfare and high-quality science. There is an
inherent reluctance to question and challenge established
practices and cultures, and even where evidence exists to
improve animal welfare or increase experimental validity,
routine or uniform implementation does not yet exist. A
systematic overview of research areas to understand the
gaps that intended research seeks to address would be
useful, but resource and skills to undertake such research
are required. It is not reasonable to envisage that in vivo
researchers alone should shoulder such responsibility; meta-
research is a fast-developing discipline that is further
complicated by the high rate with which we accrue data and
studies are being published. 
A formal framework to assess the 3Rs and 3Vs requires a
nuanced approach that takes into consideration the stage in
the research pipeline for which ethical approval is being
sought and how it fits into the broader research landscape of
a research area. For example, in exploratory research
seeking to test the effectiveness of a novel treatment in a
model of human disease, a framework to assess the external
validity is complex. It may be that this treatment is being
developed in a single laboratory, and whilst the external
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validity of such a study is likely to be restricted, due to
limited sampling across the reaction norm, it is important
that the limits to the generalisability of the proposed study
are considered in the context of the proposed research
question. This consideration should be described at all
stages of the research lifecycle, from proposals submitted to
funders, ethical approval applications and any resulting
publications or other modes of dissemination of research
findings. However, if ethical approval is being sought for a
confirmatory study; one that seeks to determine the effec-
tiveness of this intervention to inform clinical trial design,
the research design should be externally valid. We envisage
that such a study samples appropriately from the reaction
norm, or that the desire to replicate a study, for which an
effect has been observed in a single centre exploratory
study, to demonstrate external validity is not penalised. To
perform an informed assessment of the likelihood of
benefit, particularly in terms of the external validity, a
systematic review that details the range of conditions that
the intervention has demonstrated effectiveness is required.
An assessment of the use of measures to reduce risks of
bias, to ensure internal validity, and the limits to the
construct validity in terms of models and outcome measures
that have been sampled are also required. This is a substan-
tial undertaking and would require investment of resources
to perform such activities that funding agencies should
consider as due diligence prior to further investment of
larger more resource-intense research studies. We do not
advocate that animal research should only be performed in
light of a systematic review of relevant evidence. However,
when considering the undertaking of large, potentially
multi-centre, confirmatory studies, it would be prudent to
ensure the premise of such a study is robust. We call for
more meta-research, on which researchers and ethics
committees can draw upon in their decision-making. 
There is scope to employ a scoring system of pre-defined
measures to assess internal validity, including plans for
randomisation and blinding, across the life sciences. There
may be cases where blinding or randomisation are not
feasible (eg fur colour differs between cohorts) and this
should be considered. Further, findings should be reported
irrespective of the direction of effect to ensure that the
animals used contribute to our accumulation of knowledge.
To protect against reporting biases, particularly in confirma-
tory research, it would be appropriate for the investigators to
assure a priori registration of their study protocol which
details the experimental design, planned outcomes and
analysis plan. Advocated by the Centre for Science (COS),
registered reports are a type of publication that seeks to
address many of these issues. The concept revolves around
the quality of a research question and methodology by peer
review of an introduction and methods prior to any data
collection. High-quality protocols, which detail experi-
mental design, planned outcomes and analysis plan are
registered and the completed study is provisionally accepted
for publication if the authors follow the registered method-
ology (Chambers et al 2014). 
Unlike the 3Vs, formal assessment of the 3Rs is already
embedded in our assessment of HBA but much of this
appears to be a qualitative undertaking. There is scope to
introduce a more systematic approach to understanding
potential 3Rs options. For example, this may include
empirical and comprehensive evidence of the impact of
housing and husbandry choices on measures of welfare.
Further, as 3Rs alternatives become available, it is
important that approaches for their dissemination are fit-
for-purpose and that the validity of this evidence is robust.
The NC3Rs/F1000 portal seeks to address this for NC3Rs-
funded researchers but dissemination strategies beyond
this cohort of researchers are required. For reduction,
which may be approached in an empirical manner, partic-
ularly in confirmatory research, sample size calculations
ought to be performed. As efforts continue to develop
novel methods to measure welfare or to develop alterna-
tives to animal research, it is important that systematic
investigation continues to cycle through testing and evalu-
ation of recommendations. 
HBAs are a prospective analysis but there is opportunity to
perform retrospective HBA analyses that have the potential to
improve substantially the HBA process. Since 2014,
European legislation requires the recording of actual harms
suffered by individual animals with the view to refine severity
categories of procedures for prospective analyses. Expanding
such retrospective analyses to include assessment of benefits,
through meta-research, has the potential to inform retrospec-
tive HBA analysis. A recent study (Pound & Nicol 2018)
sought to operationalise retrospective HBA using Bateson’s
cube as a framework. Their approach was somewhat different
to our proposal here but is the first time, as far as we are
aware, systematic retrospective HBA has been attempted.
Even in research areas where there was high concordance
between animal and clinical findings, and benefit has been
realised in terms of clinical use, none of the 212 studies were
considered ethical using this framework. To determine this,
212 studies were categorised by severity of harms to animals
and the benefit was assessed in terms of clinical relevance.
Pound and Nicol concluded that many animals suffered
severe harms that were not associated with benefits for
humans and only a small proportion of studies minimised
harms to animals whilst being associated with human benefit.
In considering benefit it is important to acknowledge the
mechanism with which the findings from animal research is
assessed and how the potential benefits are implemented at
the next stage of research. Systematic approaches that focus
on the validity of research findings have been proposed to
determine the certainty of evidence of pre-clinical animal
research and whether sufficient high-quality evidence exists
prior to embarking upon human clinical trial (Hooijmans
et al 2018). This Grading of Recommendations,
Assessment, Development, and Evaluation (GRADE)
approach uses a framework that includes aspects of the 3Vs
in this assessment. It is also important to consider that
downstream research in humans that is informed by animal
research (phase I/II clinical trials) undergoes a risk-harm
analysis during the ethical approval process that is often
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informed by pre-clinical research. In a study of investigator
brochures that are submitted for ethics review, the quality of
the animal research cited was limited (Wieschowski et al
2018). Less than 5% of the animal studies cited reported a
sample size calculation, randomisation and blinding; 89%
were not published and the majority (82%) only described
positive finding. A similar approach to understanding the
likelihood of benefit based on the 3Vs would be a useful
approach in this context. 
Animal welfare implications
The HBA process could be improved by the addition of
empirical assessment of the 3Rs and the 3Vs. By quantifying
these factors, we can evaluate whether harms are justified
and that harms are minimised and balanced against the like-
lihood of benefit. An important animal welfare implication is
that such a meta-approach allows for an evidence-based
process to improve animal welfare and underscores a
framework to prevent animals being subjected to harms
where the benefits are unlikely to be reached. Formal appli-
cation of HBA is only required for animals protected by
legislation but the ethical consideration of harms and
benefits are applied more broadly in our societal interaction
with animals. This is not just an issue for laboratory science,
there are many settings where animal welfare is important
and could benefit from a systematic approach to assessing
welfare and the totality of evidence that could be applied to
decisions; for example, environmental enrichment
approaches for farm or zoo animals. There is scope to
undertake meta-approaches across different settings to
determine consistency across settings and species. 
Conclusion
In considering Bateson’s three axes, our assessment of 3Rs
and 3Vs focuses on (i) the degree of animal suffering and (ii)
the quality of the research. The third axis, (iii) benefit of the
findings, relies on the unmet need addressed by the research
question. In this paper, this has focused on unmet medical
need (eg therapies for stroke or chronic pain). There is clear
consensus that animal research should have evident benefits,
be of high quality and cause minimal suffering to the animal.
However, the mode with which to operationalise this is less
clear. Undertaking meta-research to support study protocols
considered in HBA will provide a robust framework to
assess both the 3Rs and the 3Vs. This approach would
ensure that the entirety of relevant literature is considered
when estimating the magnitude of harms that may be
inflicted and that changes introduced are evidence-based.
Further, by considering the intended beneficiaries of an
experiment and quantifying the experimental validity, it may
be that these benefits will be substantially more realistic.
Focusing on the 3Vs provides the capacity to ensure that a
study is robust and contributes to our distillation of knowledge,
which is likely to be in small increments rather than a large
unsubstantiated claim of a benefit to humanity that is seldom
realised from a single study. This approach hopefully will
increase levels of trust in the research conducted and ensure the
validity of the knowledge gained from these experiments.
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